ACE Inhibitors vs ARBs Nursing: Same System, Different Step

Part of the Pharmacology nursing study guide. Not sure this is your weak area? Take the free study check first.

Angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) target the same regulatory cascade to lower blood pressure and reduce cardiac workload, but they interrupt the pathway at different sequential points. ACE inhibitors block the chemical conversion of angiotensin I to angiotensin II upstream, while ARBs prevent angiotensin II from binding to its tissue receptors downstream. Because ACE inhibitors simultaneously prevent the breakdown of inflammatory mediators in the lungs, they trigger a persistent dry cough that ARBs do not produce.

Both medication classes serve as foundational antihypertensives nursing interventions for managing hypertension, heart failure, and diabetic nephropathy. Understanding the precise biochemical point of action allows you to anticipate adverse effects, identify shared hemodynamic risks, and prioritize clinical assessments when caring for clients on these therapies.

ACE inhibitors and ARBs both decrease blood pressure and reduce cardiac workload by targeting the renin-angiotensin-aldosterone system. ACE inhibitors block angiotensin-converting enzyme, causing bradykinin accumulation and a dry cough. ARBs block angiotensin II receptors directly without raising bradykinin, providing an alternative when patients cannot tolerate the ACE inhibitor cough.

How RAAS nursing principles dictate where ACE inhibitors and ARBs act

The renin-angiotensin-aldosterone system (RAAS) regulates systemic blood pressure, intravascular volume, and sodium-potassium balance. When renal perfusion drops or systemic blood pressure falls, the kidneys release renin into the bloodstream. Renin cleaves circulating angiotensinogen into angiotensin I.

Angiotensin-converting enzyme, found primarily in pulmonary vascular endothelium, converts inactive angiotensin I into angiotensin II. Angiotensin II acts as a potent direct vasoconstrictor and stimulates the adrenal cortex to release aldosterone. Aldosterone acts on the distal renal tubules to retain sodium and water while excreting potassium.

ACE inhibitor mechanism of action

ACE inhibitors interfere with the enzyme responsible for converting angiotensin I to angiotensin II. By blocking this conversion, these drugs reduce circulating levels of angiotensin II, leading to systemic vasodilation and decreased aldosterone secretion. Decreased aldosterone causes the kidneys to excrete sodium and water while retaining potassium.

The enzyme target of ACE inhibitors is also responsible for degrading bradykinin, a vasodilating peptide in bronchial tissues. When an ACE inhibitor blocks this enzyme, bradykinin accumulates in the respiratory tract. This accumulation irritates airway sensory nerves, producing the classic non-productive dry cough.

ARB mechanism of action

ARBs selectively block the angiotensin II type 1 receptor sites located on vascular smooth muscle and the adrenal cortex. Angiotensin II is still synthesized in the body, but it cannot bind to its receptor to exert its vasoconstrictive and aldosterone-stimulating effects.

Because ARBs act on the receptor rather than the enzyme itself, they do not inhibit the breakdown of bradykinin. Bradykinin levels remain baseline, which explains why clients taking ARBs do not develop the drug-induced cough associated with ACE inhibitors.

Recognizing suffixes and classifying pril vs sartan nursing drugs

Identifying these medications on board exams and clinical drug records relies on recognizing standardized drug suffixes. Remembering the distinction between the suffixes helps you immediately anticipate the side effect profile.

• ACE Inhibitors: End in the suffix -pril (for example, lisinopril, enalapril, captopril, ramipril, benazepril).
• ARBs: End in the suffix -sartan (for example, losartan, valsartan, candesartan, irbesartan, olmesartan).

For detailed monograph data and official prescribing information on specific formulations, consult resources like DailyMed or MedlinePlus drug information.

When reviewing client chart documentation during clinical rotations, group these agents by their suffix to streamline your pre-administration assessment routines.

Critical shared risks: potassium, kidney function, and pregnancy

While their effects on bradykinin differ, ACE inhibitors and ARBs share major systemic safety risks due to their identical downstream impact on aldosterone and renal hemodynamics.

Risk of hyperkalemia

Suppression of aldosterone secretion decreases potassium excretion in the collecting ducts of the kidney. As a result, both ACE inhibitors and ARBs carry a risk of elevated serum potassium levels. Combine these medications with potassium-sparing diuretics or oral potassium supplements with caution, and evaluate electrolyte shifts using standard guidelines for hyperkalemia vs hypokalemia nursing assessment.

If you are unsure whether cardiovascular pharmacology is your primary weak area, complete the free assessment at 60-second study check before structuring your review schedule.

Alterations in renal perfusion

Angiotensin II preferentially constricts the efferent arterioles of the renal glomeruli to maintain intraglomerular pressure and filtration rates. When ACE inhibitors or ARBs remove angiotensin II activity, efferent arterioles dilate. This dilation reduces glomerular filtration pressure.

In clients with pre-existing renal artery stenosis, severe volume depletion, or heart failure, this reduction in filtration pressure can lead to acute renal impairment. Monitor serum creatinine and blood urea nitrogen trends closely following therapy initiation or dose titration.

Teratogenic potential

Both ACE inhibitors and ARBs carry a black box warning for pregnancy. Inhibiting the renin-angiotensin system during the second and third trimesters leads to fetal renal dysgenesis, oligohydramnios, skeletal deformations, and fetal death. Discontinue these agents immediately if pregnancy is detected.

Risk of angioedema

Angioedema is a rapid, localized swelling of the dermis, subcutaneous tissue, mucosa, and submucosal tissues. It presents most commonly as swelling of the lips, tongue, glottis, and larynx, posing a severe airway compromise hazard.

Angioedema occurs far more frequently with ACE inhibitors due to elevated bradykinin levels, but it can occasionally occur with ARBs through alternative pathways. A history of angioedema from an ACE inhibitor is generally considered a strong contraindication for receiving another ACE inhibitor, and ARBs must be introduced with extreme caution under specialized provider supervision.

Managing the ACE inhibitor cough and switching to ARBs

The ACE inhibitor cough nursing management pathway centers on identifying the characteristic features of the symptom and knowing the correct clinical response.

The cough is typically:

• Dry, hacking, and non-productive.
• Unresponsive to standard over-the-counter cough suppressants or bronchodilators.
• Independent of medication timing or dosage strength.
• Reversible within days or weeks of drug discontinuation.

Do not mistake this dry cough for pulmonary edema or heart failure exacerbation, which present with wet crackles, tachypnea, orthopnea, and pink frothy sputum. Cross-reference clinical presentation against angina vs myocardial infarction nursing priorities when evaluating concomitant chest discomfort or dyspnea.

When a client reports a persistent, uncomfortable dry cough while taking an ACE inhibitor, educate them never to stop the medication abruptly without medical guidance. The standard care plan involves notifying the prescribing provider, who will typically transition the client from the pril agent to a sartan agent to preserve RAAS suppression without bradykinin accumulation.

Direct comparison: ACE inhibitors vs ARBs nursing summary

The following table synthesizes key clinical operational parameters when evaluating ACE inhibitors vs ARBs:

Essential ACE inhibitors nursing considerations and ARBs nursing considerations

Comprehensive ACE inhibitors nursing considerations and ARBs nursing considerations involve structured assessment steps prior to administration, ongoing monitoring, and focused client teaching.

Pre-administration baseline assessment

1. Hemodynamic Status: Measure resting blood pressure and pulse rate. Hold the medication and notify the provider if parameters fall below institutional or provider-set cutoffs.
2. Laboratory Trends: Review serum potassium, blood urea nitrogen, and serum creatinine. Compare recent values against baseline trends established by your health system.
3. Pregnancy Status: Confirm negative pregnancy test results in females of childbearing potential prior to starting therapy.

Inpatient monitoring and safety

• First-Dose Orthostatic Hypotension: The initial dose can cause a precipitous drop in blood pressure, especially in volume-depleted clients taking concomitant diuretics. Assist clients with ambulation and instruct them to change positions slowly.
• Fluid Balance: Monitor daily weight, input, and output to detect acute renal functional changes.

Client education priorities

• Dietary Awareness: Instruct clients to avoid potassium supplements and salt substitutes that replace sodium with potassium, as these compound the hyperkalemia risk.
• Adverse Symptom Reporting: Teach clients to immediately report facial swelling, lip numbness, tongue enlargement, or difficulty breathing, which signal life-threatening angioedema.
• Cough Management: Inform clients taking ACE inhibitors that a persistent dry cough is a known side effect that requires medication modification rather than self-treatment with cough syrup.

Worked NCLEX-style exam question with rationale

Scenario

A nurse in an outpatient clinic reviews the chart of a client diagnosed with hypertension and heart failure. The client has been taking lisinopril for three weeks and reports a continuous, dry, tickling cough that disrupts sleep. Vital signs are within baseline limits, lung sounds are clear throughout all fields, and no peripheral edema is noted. Which action should the nurse take first?

• A. Administer a PRN dose of an over-the-counter antitussive medication.
• B. Document the finding as a common non-urgent effect and advise continuing the drug.
• C. Notify the healthcare provider to evaluate transitioning the client to an ARB such as losartan.
• D. Request a prescription for a bronchodilator inhalation solution to treat airway irritation.

Correct Answer: C

Rationale: The client’s presentation (dry, continuous cough without pulmonary crackles or congestion) is a classic adverse effect of ACE inhibitor therapy caused by bradykinin accumulation. Antitussives and bronchodilators do not address the underlying biochemical mechanism. The standard management strategy for ACE inhibitors vs ARBs nursing scenarios is to discontinue the ACE inhibitor and initiate an ARB (such as losartan), which provides equivalent RAAS inhibition without inducing bradykinin-mediated cough.

Distractor Analysis

• Option A is incorrect: Antitussive medications target central or local cough reflex pathways but fail to resolve bradykinin-induced tracheal irritation. Providing an ineffective symptom remedy delays appropriate medication substitution.
• Option B is incorrect: While the cough is a known adverse effect, ignoring a sleep-disrupting cough leads to non-compliance. The nurse must advocate for a medication modification rather than telling the client to endure the discomfort indefinitely.
• Option D is incorrect: The ACE inhibitor cough is caused by inflammatory peptide accumulation in bronchial mucosa, not bronchospasm. Bronchodilators will not suppress the cough and expose the client to unnecessary sympathomimetic side effects like tachycardia.

Common student confusions about ACE inhibitors vs ARBs

Confusion 1: Assuming ARBs lower potassium levels because they replace ACE inhibitors

Students often incorrectly assume that because ARBs are given when a client reacts to an ACE inhibitor, their side effect profiles are opposites. In reality, both drug classes suppress aldosterone secretion. Therefore, both ACE inhibitors and ARBs increase serum potassium levels and require identical hyperkalemia monitoring precautions.

Confusion 2: Expecting ACE inhibitors and ARBs to decrease heart rate

Because both drug classes treat hypertension and heart failure, students often confuse them with beta-blockers or non-dihydropyridine calcium channel blockers. Neither ACE inhibitors nor ARBs directly block cardiac beta receptors or slow SA node conduction. They lower systemic vascular resistance and blood pressure without lowering pulse rate.

Confusion 3: Treating the ACE inhibitor cough as an allergic reaction

The dry cough is an expected pharmacological side effect of bradykinin buildup, not an IgE-mediated type I hypersensitivity reaction. However, angioedema is an emergency reaction. You must clearly differentiate between the harmless but annoying dry cough and the life-threatening swelling of facial tissues.

If you want the whole plan built around this, check out the Nursing Study OS ($19, one-time payment, no recurring subscription).

Key takeaways

• ACE inhibitors block angiotensin-converting enzyme to reduce angiotensin II, while ARBs directly block angiotensin II type 1 receptors on target tissues.
• Accumulation of bradykinin during ACE inhibitor therapy causes a dry, persistent cough that does not occur during ARB therapy.
• Recognize ACE inhibitors by the suffix “-pril” and ARBs by the suffix “-sartan”.
• Both medication classes carry serious shared risks of hyperkalemia, acute reductions in glomerular filtration, teratogenicity during pregnancy, and angioedema.
• Teach clients on either medication class to avoid potassium-based salt substitutes and to report any swelling of the lips, tongue, or throat immediately.
• When a client cannot tolerate an ACE inhibitor due to a persistent dry cough, expect the provider to switch the client to an ARB to maintain blood pressure control.

Sources & review

This guide is an original educational summary written from the sources below. Each URL was verified on the date recorded in our source registry.

• Physiology, Renin Angiotensin System (StatPearls) — U.S. National Library of Medicine
• Drugs, Herbs and Supplements — U.S. National Library of Medicine
• About High Blood Pressure — Centers for Disease Control and Prevention

How we write and review clinical content →